254 related articles for article (PubMed ID: 24677555)
1. Associations of FGF-23 and sKlotho with cardiovascular outcomes among patients with CKD stages 2-4.
Seiler S; Rogacev KS; Roth HJ; Shafein P; Emrich I; Neuhaus S; Floege J; Fliser D; Heine GH
Clin J Am Soc Nephrol; 2014 Jun; 9(6):1049-58. PubMed ID: 24677555
[TBL] [Abstract][Full Text] [Related]
2. Fibroblast Growth Factor 23 and α-Klotho Protein Are Associated with Adverse Clinical Outcomes in Non-Dialysis CKD Patients.
Manou E; Thodis E; Arsos G; Pasadakis P; Panagoutsos S; Papadopoulou D; Papagianni A
Kidney Blood Press Res; 2020; 45(6):900-915. PubMed ID: 33040068
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast growth factor-23 and cardiovascular events in CKD.
Scialla JJ; Xie H; Rahman M; Anderson AH; Isakova T; Ojo A; Zhang X; Nessel L; Hamano T; Grunwald JE; Raj DS; Yang W; He J; Lash JP; Go AS; Kusek JW; Feldman H; Wolf M;
J Am Soc Nephrol; 2014 Feb; 25(2):349-60. PubMed ID: 24158986
[TBL] [Abstract][Full Text] [Related]
4. Association of Nonoxidized Parathyroid Hormone with Cardiovascular and Kidney Disease Outcomes in Chronic Kidney Disease.
Seiler-Mussler S; Limbach AS; Emrich IE; Pickering JW; Roth HJ; Fliser D; Heine GH
Clin J Am Soc Nephrol; 2018 Apr; 13(4):569-576. PubMed ID: 29507005
[TBL] [Abstract][Full Text] [Related]
5. Plasma Klotho is not related to kidney function and does not predict adverse outcome in patients with chronic kidney disease.
Seiler S; Wen M; Roth HJ; Fehrenz M; Flügge F; Herath E; Weihrauch A; Fliser D; Heine GH
Kidney Int; 2013 Jan; 83(1):121-8. PubMed ID: 22895520
[TBL] [Abstract][Full Text] [Related]
6. [Role of the morphogenetic proteins FGF-23 and Klotho and the glycoprotein sclerostin in the assessment of the risk of cardiovascular diseases and the prognosis of chronic kidney disease].
Milovanova LY; Milovanov YS; Kudryavtseva DV; Markina MM; Milovanova SY; Kozlovskaya LV; Lebedeva MV; Beketov VD; Moiseev SV; Mukhin NA; Fomin VV; Svistunov AA
Ter Arkh; 2015; 87(6):10-16. PubMed ID: 26281189
[TBL] [Abstract][Full Text] [Related]
7. Klotho, fibroblast growth factor-23, and the renin-angiotensin system - an analysis from the PEACE trial.
Bergmark BA; Udell JA; Morrow DA; Jarolim P; Kuder JF; Solomon SD; Pfeffer MA; Braunwald E; Sabatine MS
Eur J Heart Fail; 2019 Apr; 21(4):462-470. PubMed ID: 30773798
[TBL] [Abstract][Full Text] [Related]
8. Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study).
Ix JH; Katz R; Kestenbaum BR; de Boer IH; Chonchol M; Mukamal KJ; Rifkin D; Siscovick DS; Sarnak MJ; Shlipak MG
J Am Coll Cardiol; 2012 Jul; 60(3):200-7. PubMed ID: 22703926
[TBL] [Abstract][Full Text] [Related]
9. Fibroblast growth factor 23 and sudden versus non-sudden cardiac death: the Cardiovascular Health Study.
Deo R; Katz R; de Boer IH; Sotoodehnia N; Kestenbaum B; Mukamal KJ; Chonchol M; Sarnak MJ; Siscovick D; Shlipak MG; Ix JH
Am J Kidney Dis; 2015 Jul; 66(1):40-6. PubMed ID: 25572028
[TBL] [Abstract][Full Text] [Related]
10. Strength of Fibroblast Growth Factor 23 as a Cardiovascular Risk Predictor in Chronic Kidney Disease Weaken by ProBNP Adjustment.
Emrich IE; Brandenburg V; Sellier AB; Schauerte J; Wiedenroth J; Untersteller K; Lennartz CS; Seiler-Mussler S; Wagenpfeil S; Fliser D; Heine GH
Am J Nephrol; 2019; 49(3):203-211. PubMed ID: 30808827
[TBL] [Abstract][Full Text] [Related]
11. [New markers of cardio-renal links in chronic kidney disease].
Milovanova LIu; Milovanov IuS; Kozlovskaia LV; Mukhin NA
Ter Arkh; 2013; 85(6):17-24. PubMed ID: 23866594
[TBL] [Abstract][Full Text] [Related]
12. Soluble Klotho, a Potential Biomarker of Chronic Kidney Disease-Mineral Bone Disorders Involved in Healthy Ageing: Lights and Shadows.
Martín-Vírgala J; Martín-Carro B; Fernández-Villabrille S; Ruiz-Torres MP; Gómez-Alonso C; Rodríguez-García M; Fernández-Martín JL; Alonso-Montes C; Panizo S; Cannata-Andía JB; Naves-Díaz M; Carrillo-López N
Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339121
[TBL] [Abstract][Full Text] [Related]
13. Serum and Urinary Soluble α-Klotho as Markers of Kidney and Vascular Impairment.
Martín-Vírgala J; Fernández-Villabrille S; Martín-Carro B; Tamargo-Gómez I; Navarro-González JF; Mora-Fernández C; Calleros L; Astudillo-Cortés E; Avello-Llano N; Mariño G; Dusso AS; Alonso-Montes C; Panizo S; Cannata-Andía JB; Naves-Díaz M; Carrillo-López N
Nutrients; 2023 Mar; 15(6):. PubMed ID: 36986200
[TBL] [Abstract][Full Text] [Related]
14. Soluble Klotho is not independently associated with cardiovascular disease in a population of dialysis patients.
Buiten MS; de Bie MK; Bouma-de Krijger A; van Dam B; Dekker FW; Jukema JW; Rabelink TJ; Rotmans JI
BMC Nephrol; 2014 Dec; 15():197. PubMed ID: 25495997
[TBL] [Abstract][Full Text] [Related]
15. Plasmatic Klotho and FGF23 Levels as Biomarkers of CKD-Associated Cardiac Disease in Type 2 Diabetic Patients.
Silva AP; Mendes F; Carias E; Gonçalves RB; Fragoso A; Dias C; Tavares N; Café HM; Santos N; Rato F; Leão Neves P; Almeida E
Int J Mol Sci; 2019 Mar; 20(7):. PubMed ID: 30934737
[TBL] [Abstract][Full Text] [Related]
16. Effect of essential amino acid кetoanalogues and protein restriction diet on morphogenetic proteins (FGF-23 and Кlotho) in 3b-4 stages chronic кidney disease patients: a randomized pilot study.
Milovanova L; Fomin V; Moiseev S; Taranova M; Milovanov Y; Lysenko Kozlovskaya L; Kozlov V; Kozevnikova E; Milovanova S; Lebedeva M; Reshetnikov V
Clin Exp Nephrol; 2018 Dec; 22(6):1351-1359. PubMed ID: 29948444
[TBL] [Abstract][Full Text] [Related]
17. Circulating α-klotho levels in CKD and relationship to progression.
Kim HR; Nam BY; Kim DW; Kang MW; Han JH; Lee MJ; Shin DH; Doh FM; Koo HM; Ko KI; Kim CH; Oh HJ; Yoo TH; Kang SW; Han DS; Han SH
Am J Kidney Dis; 2013 Jun; 61(6):899-909. PubMed ID: 23540260
[TBL] [Abstract][Full Text] [Related]
18. The FGF23-Klotho axis and cardiac tissue Doppler imaging in pediatric chronic kidney disease-a prospective cohort study.
Tranæus Lindblad Y; Olauson H; Vavilis G; Hammar U; Herthelius M; Axelsson J; Bárány P
Pediatr Nephrol; 2018 Jan; 33(1):147-157. PubMed ID: 28795324
[TBL] [Abstract][Full Text] [Related]
19. Lipids, Apolipoproteins, and Risk of Atherosclerotic Cardiovascular Disease in Persons With CKD.
Bajaj A; Xie D; Cedillo-Couvert E; Charleston J; Chen J; Deo R; Feldman HI; Go AS; He J; Horwitz E; Kallem R; Rahman M; Weir MR; Anderson AH; Rader DJ;
Am J Kidney Dis; 2019 Jun; 73(6):827-836. PubMed ID: 30686529
[TBL] [Abstract][Full Text] [Related]
20. Fibroblast growth factor-23 (FGF-23) / soluble Klotho protein (sKlotho) / sclerostin glycoprotein ratio disturbance is a novel risk factor for cardiovascular complications in ESRD patients receiving treatment with regular hemodialysis or hemodiafiltration.
Milovanova LY; Dobrosmyslov IA; Milovanov YS; Taranova MV; Kozlov VV; Milovanova SY; Kozevnikova EI
Ter Arkh; 2018 Jun; 90(6):48-54. PubMed ID: 30701904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
